The Relation Between Post-Operative Surgical Site Infection and Time to Start Adjuvant Treatment in Ovarian and Uterine Cancers.

IF 3.4 4区医学 Q2 ONCOLOGY

Current oncology Pub Date : 2025-08-21 DOI:10.3390/curroncol32080474

Karlijn M C Cornel, Julie My Van Nguyen, Lilian T Gien, Allan Covens, Danielle Vicus

{"title":"The Relation Between Post-Operative Surgical Site Infection and Time to Start Adjuvant Treatment in Ovarian and Uterine Cancers.","authors":"Karlijn M C Cornel, Julie My Van Nguyen, Lilian T Gien, Allan Covens, Danielle Vicus","doi":"10.3390/curroncol32080474","DOIUrl":null,"url":null,"abstract":"Surgical site infections (SSIs) occur in 10-15% of patients and are linked to up to 29% of delays in starting adjuvant treatment. This study assessed the association between SSIs in patients with ovarian and uterine cancer and their impact on time to adjuvant therapy and oncologic outcomes. Patients who underwent surgery from 1 January 2015 to 30 September 2017 were included, using institutional National Surgical Quality Improvement Program (NSQIP) data and chart reviews. Among 371 patients (median follow-up 4.1 years), 243 (65.5%) received adjuvant treatment. The median time to start was 39 days for chemotherapy, 61 days for radiotherapy, and 42 days for combined therapy (p < 0.001). Patients with ovarian cancer began treatment sooner than those with uterine cancer (39 vs. 52 days, p < 0.001), but no significant difference was observed between those with or without SSIs. In 238 patients with uterine cancer, those with SSIs had a twofold higher recurrence risk (HR 1.97, p = 0.022) and over threefold lower overall survival (HR 3.45, p = 0.018). Multivariable analysis showed that surgical route and disease stage were independent predictors; SSI was not an independent factor. No survival difference related to SSIs was found in patients with ovarian cancer. Further research is needed to clarify the impact of SSIs on treatment timing and recurrence.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 8","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12385515/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/curroncol32080474","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Surgical site infections (SSIs) occur in 10-15% of patients and are linked to up to 29% of delays in starting adjuvant treatment. This study assessed the association between SSIs in patients with ovarian and uterine cancer and their impact on time to adjuvant therapy and oncologic outcomes. Patients who underwent surgery from 1 January 2015 to 30 September 2017 were included, using institutional National Surgical Quality Improvement Program (NSQIP) data and chart reviews. Among 371 patients (median follow-up 4.1 years), 243 (65.5%) received adjuvant treatment. The median time to start was 39 days for chemotherapy, 61 days for radiotherapy, and 42 days for combined therapy (p < 0.001). Patients with ovarian cancer began treatment sooner than those with uterine cancer (39 vs. 52 days, p < 0.001), but no significant difference was observed between those with or without SSIs. In 238 patients with uterine cancer, those with SSIs had a twofold higher recurrence risk (HR 1.97, p = 0.022) and over threefold lower overall survival (HR 3.45, p = 0.018). Multivariable analysis showed that surgical route and disease stage were independent predictors; SSI was not an independent factor. No survival difference related to SSIs was found in patients with ovarian cancer. Further research is needed to clarify the impact of SSIs on treatment timing and recurrence.

Abstract Image

查看原文本刊更多论文

卵巢癌和子宫癌术后手术部位感染与开始辅助治疗时间的关系。

手术部位感染（ssi）发生在10-15%的患者中，并与多达29%的开始辅助治疗延迟有关。本研究评估了卵巢癌和子宫癌患者ssi之间的关系及其对辅助治疗时间和肿瘤预后的影响。纳入2015年1月1日至2017年9月30日接受手术的患者，使用机构国家手术质量改进计划（NSQIP）数据和图表审查。在371例患者中（中位随访4.1年），243例（65.5%）接受了辅助治疗。化疗的中位起始时间为39天，放疗为61天，联合治疗为42天（p < 0.001）。卵巢癌患者比子宫癌患者更早开始治疗（39天vs 52天，p < 0.001），但有无ssi患者之间无显著差异。在238例子宫癌患者中，ssi患者的复发风险高2倍（HR 1.97, p = 0.022），总生存期低3倍以上（HR 3.45, p = 0.018）。多变量分析显示手术途径和疾病分期是独立的预测因素；SSI不是一个独立的因素。在卵巢癌患者中未发现与ssi相关的生存差异。需要进一步的研究来阐明ssi对治疗时间和复发的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current oncology ONCOLOGY-

CiteScore

3.30

自引率

7.70%

发文量

664

审稿时长

1 months

期刊介绍： Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease. We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.